LevitasBio Launches LeviSelect Suite of Cell Depletion & Enrichment Kits
7.2.2023 15:53:00 EET | Business Wire | Press release
LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005645/en/
Five new LeviSelect Immune Cell Kits enable targeted enrichment of CD3 T Cells, CD4 T Cells, CD8 T Cells and Pan B Cells. Additional kits are also available under early access. (Graphic: Business Wire)
LeviSelect Kits are a targeted expansion of the revolutionary LeviCell™ Advanced Workflow fully integrated protocol that delivers an important new approach to cellular isolation and analysis, offering:
- Cells of interest are entirely label-free, unmodified or unperturbed with no gene expression or activation changes
- Live-cell enrichment, debris removal, and targeted selection all occur in a single simple step with no additional purifications, filtrations or consumables required
- Multiple LeviSelect kits can be multiplexed for a powerful and extremely targeted approach
For oncology or immuno-oncology research, LeviSelect CD45 Depletion Kits provide a highly effective method for the enrichment of pure tumor cells enabling characterization for drug discovery and biomarker identification.
LeviSelect Immune Kits support target selection of the immune subpopulations required for downstream cell analysis or further subsetting. Researchers can enrich hematopoietic populations quickly without lengthy workflows or potential cell activation.
- CD3 Enrichment
- CD4 Enrichment
- CD8 Enrichment
- Pan B Enrichment
- Pan Monocyte Enrichment
- NK Cell Enrichment
- Neutrophil Enrichment
Now T Cells, B Cells, NK Cell and Monocytes can be enriched simultaneously with viable cell enrichment in an untouched and unbiased manner. Future LeviSelect kits will include subtypes from these major populations.
“With the immediate launch of seven LeviSelect Kits—and six more available via our Early Access program—LevitasBio is enabling the streamline enrichment of these cells for downstream cell-based assays or immune profiling studies,” stated Martin Pieprzyk, CEO of LevitasBio. “This is highly impactful to catalyze novel discoveries in both academic and biopharma discovery research.”
Researchers, scientists, and labs who would like exclusive, priority access to future LeviSelect Kits can join the LevitasBio Early Access Program at https://levitasbio.com/early-access-program.
LevitasBio —True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005645/en/
Contact information
Steven Collier
Communication Liaison
steve@levitasbio.com
650-229-8596
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the checkout flow and assert the console has no errors." "Log in and store the session cookie value." "Assert localStorage contains the selected product ID." "Open th
Allegro DVT’s Pulsar Decoder IP Adds Support for AV2 Video Codec16.6.2026 15:30:00 EEST | Press release
Allegro DVT, the leader in Semiconductor Video IPs and Video Compliance Tools, announces the availability its real-time AV2 Decoder IP integrated into its Pulsar™ D400 Series Multi-Standard Decoding IP. This milestone is a follow-up to the company’s announcement in September 2026 that underscored its plans to develop solutions for the emerging AV2 ecosystem spanning both video compliance tools and semiconductor IPs. As global demand for high-quality streaming continues to accelerate, AV2 is emerging as the next major open, royalty-free video compression standard. Developed by the Alliance for Open Media (AOM), AV2 represents a generational leap in video coding, designed to address evolving streaming requirements and enable new media experiences. Building on the success of AV1, AV2 introduces capabilities that support advanced applications such as immersive content (AR/VR), multi-view and split-screen streaming, and improved screen content handling, while operating across a wider range
Sai Life Sciences Achieves EcoVadis Platinum Rating, Joining the Top 1% of Companies Assessed Worldwide16.6.2026 15:27:00 EEST | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616260047/en/ Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment
Plaud Scales From $1M to $100M ARR Within Two Years, Bringing AI Beyond the Screen for Professionals16.6.2026 15:25:00 EEST | Press release
Plaud, the company building real-world AI interface for professionals, today announced it has scaled from $1M to $100M in ARR within two years, placing it among the fastest AI companies globally to reach the milestone. Plaud is the only hardware-enabled AI company in a cohort otherwise dominated by software-only players, and now serves more than 2 million professionals across 170+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616945160/en/ The fastest AI growth stories have, until now, belonged almost entirely to software-native companies: AI coding tools, enterprise workflow agents, and other SaaS products scaling behind screens and keyboards. Plaud's growth represents a different model — recurring AI software scaled through a real-world physical interface, with devices (Plaud Note, Plaud Note Pro, Plaud NotePin S) acting as the entry point into human conversations, capturing the upstream, lossless, source-of
Rehlko Integrates WB Power Services into its UK and EMEA Platform, Expanding Lifecycle Capabilities for Mission-Critical Power16.6.2026 15:00:00 EEST | Press release
Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, today announced that its UK business, formerly WB Power Services, has been fully brought onto the Rehlko platform, strengthening the company’s UK and Europe, Middle East, and Africa (EMEA) operating model and expanding its ability to deliver end-to-end lifecycle solutions for mission-critical power applications. The move aligns the former WB Power Services’ long-established UK capabilities – including engineering, installation, commissioning, and long-term service – with Rehlko’s broader platform. It represents an important step in scaling consistent, high-quality delivery across priority markets as demand accelerates in data centers and other mission-critical environments. Customers increasingly require partners that can deliver reliable, repeatable solutions across the full project lifecycle and over long operating horizons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom